

Northbaze Q4 2022 - Review

Redeye provides an update on Northbaze's Q4 2022 report. Despite facing challenges, the company achieved solid growth. However, non-recurring costs led to a temporary dip in margins. While we made minor changes to our estimates, we have left our fair value range unchanged.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

Northbaze Q4 2022 - Review